Nifty
Sensex
:
:
23913.70
76009.70
-118.00 (-0.49%)
-479.26 (-0.63%)

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 500420 | NSE: TORNTPHARM

4452.10
26-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  4572.3
  •  4595.2
  •  4413
  •  4572.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  506176
  •  2256511846.7
  •  4712.9
  •  3102

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,50,648.83
  • 71.54
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,64,281.83
  • 0.85%
  • 18.44

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 68.31%
  • 0.33%
  • 4.11%
  • FII
  • DII
  • Others
  • 16.18%
  • 6.49%
  • 4.58%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.62
  • 7.55
  • 6.18

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.10
  • 8.36
  • 5.58

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.98
  • 8.83
  • 15.35

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 56.99
  • 59.73
  • 59.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.74
  • 11.45
  • 13.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.46
  • 26.26
  • 29.94

Earnings Forecasts:

(Updated: 23-05-2026)
Description
2024
2025
2026
2027
Adj EPS
70.58
81.62
103.35
121.67
P/E Ratio
64.79
56.02
44.24
37.58
Revenue
13431.5
16543.2
18433.5
20206.4
EBITDA
4392.04
5496.12
6299.52
6941.31
Net Income
2395.72
2816.1
3580.64
4096.42
ROA
14.24
15.44
17.15
17.96
P/B Ratio
16.96
13.55
10.62
6.94
ROE
28.31
26.85
26.83
22.6
FCFF
2008.94
3471.89
4326.22
5935.07
FCFF Yield
1.32
2.28
2.84
3.89
Net Debt
6416.89
4828.33
2558.38
3551.1
BVPS
269.65
337.4
430.72
658.95

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
4,197.00
2,959.00
41.84%
3,303.00
2,809.00
17.59%
3,302.00
2,889.00
14.30%
3,178.00
2,859.00
11.16%
Expenses
2,841.00
1,995.00
42.41%
2,215.00
1,895.00
16.89%
2,219.00
1,950.00
13.79%
2,146.00
1,955.00
9.77%
EBITDA
1,356.00
964.00
40.66%
1,088.00
914.00
19.04%
1,083.00
939.00
15.34%
1,032.00
904.00
14.16%
EBIDTM
32.31%
32.58%
32.94%
32.54%
32.80%
32.50%
32.47%
31.62%
Other Income
-17.00
-18.00
-
-13.00
33.00
-
-27.00
-16.00
-
-37.00
24.00
-
Interest
236.00
56.00
321.43%
45.00
57.00
-21.05%
48.00
64.00
-25.00%
56.00
75.00
-25.33%
Depreciation
508.00
201.00
152.74%
206.00
199.00
3.52%
204.00
198.00
3.03%
201.00
197.00
2.03%
PBT
529.00
665.00
-20.45%
814.00
691.00
17.80%
791.00
661.00
19.67%
738.00
656.00
12.50%
Tax
165.00
167.00
-1.20%
179.00
188.00
-4.79%
200.00
208.00
-3.85%
190.00
199.00
-4.52%
PAT
364.00
498.00
-26.91%
635.00
503.00
26.24%
591.00
453.00
30.46%
548.00
457.00
19.91%
PATM
8.67%
16.83%
19.22%
17.91%
17.90%
15.68%
17.24%
15.98%
EPS
11.49
14.71
-21.89%
18.76
14.86
26.24%
17.46
13.38
30.49%
16.19
13.50
19.93%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
13,980.00
11,516.09
10,727.84
9,620.15
8,508.04
8,004.57
7,939.31
7,672.80
5,949.83
5,815.69
6,666.85
Net Sales Growth
21.40%
7.35%
11.51%
13.07%
6.29%
0.82%
3.47%
28.96%
2.31%
-12.77%
 
Cost Of Goods Sold
3,388.00
2,555.63
2,458.95
2,513.20
2,230.75
1,960.12
1,981.79
2,041.26
1,535.17
1,629.66
1,432.13
Gross Profit
10,592.00
8,960.46
8,268.89
7,106.95
6,277.29
6,044.45
5,957.52
5,631.54
4,414.66
4,186.03
5,234.72
GP Margin
75.77%
77.81%
77.08%
73.88%
73.78%
75.51%
75.04%
73.40%
74.20%
71.98%
78.52%
Total Expenditure
9,421.00
7,811.74
7,364.25
6,796.18
6,076.77
5,524.49
5,768.95
5,696.31
4,608.78
4,438.42
3,937.05
Power & Fuel Cost
-
137.34
145.20
155.28
144.19
122.94
128.19
132.46
118.77
107.98
92.59
% Of Sales
-
1.19%
1.35%
1.61%
1.69%
1.54%
1.61%
1.73%
2.00%
1.86%
1.39%
Employee Cost
-
2,203.37
1,984.40
1,677.69
1,526.45
1,439.62
1,429.04
1,403.79
1,135.25
993.41
842.35
% Of Sales
-
19.13%
18.50%
17.44%
17.94%
17.98%
18.00%
18.30%
19.08%
17.08%
12.63%
Manufacturing Exp.
-
594.29
570.58
570.79
591.13
550.92
544.11
558.84
457.58
502.16
353.45
% Of Sales
-
5.16%
5.32%
5.93%
6.95%
6.88%
6.85%
7.28%
7.69%
8.63%
5.30%
General & Admin Exp.
-
960.60
980.72
775.30
637.65
633.48
801.98
763.90
677.71
578.05
637.92
% Of Sales
-
8.34%
9.14%
8.06%
7.49%
7.91%
10.10%
9.96%
11.39%
9.94%
9.57%
Selling & Distn. Exp.
-
1,260.67
1,129.68
1,026.99
884.91
742.63
807.39
738.03
641.30
567.70
547.05
% Of Sales
-
10.95%
10.53%
10.68%
10.40%
9.28%
10.17%
9.62%
10.78%
9.76%
8.21%
Miscellaneous Exp.
-
99.84
94.72
76.93
61.69
74.78
76.45
58.03
43.00
59.46
547.05
% Of Sales
-
0.87%
0.88%
0.80%
0.73%
0.93%
0.96%
0.76%
0.72%
1.02%
0.47%
EBITDA
4,559.00
3,704.35
3,363.59
2,823.97
2,431.27
2,480.08
2,170.36
1,976.49
1,341.05
1,377.27
2,729.80
EBITDA Margin
32.61%
32.17%
31.35%
29.35%
28.58%
30.98%
27.34%
25.76%
22.54%
23.68%
40.95%
Other Income
-94.00
39.91
61.97
63.22
196.56
56.91
121.30
63.62
307.04
223.30
228.80
Interest
385.00
252.31
353.56
333.44
255.06
352.94
450.71
503.75
308.48
205.56
183.98
Depreciation
1,119.00
794.93
808.27
706.59
662.16
657.79
654.38
617.69
408.60
306.92
237.55
PBT
2,872.00
2,697.02
2,263.73
1,847.16
1,710.61
1,526.26
1,186.57
918.67
931.01
1,088.09
2,537.07
Tax
734.00
761.56
695.73
601.93
448.73
274.38
161.85
125.35
252.87
154.51
610.17
Tax Rate
25.56%
28.49%
29.58%
32.59%
36.60%
17.98%
13.64%
22.32%
27.16%
14.20%
26.04%
PAT
2,138.00
1,911.25
1,656.38
1,245.23
777.18
1,251.88
1,024.72
436.28
678.11
933.55
1,733.24
PAT before Minority Interest
2,163.00
1,911.25
1,656.38
1,245.23
777.18
1,251.88
1,024.72
436.31
678.14
933.58
1,733.27
Minority Interest
25.00
0.00
0.00
0.00
0.00
0.00
0.00
-0.03
-0.03
-0.03
-0.03
PAT Margin
15.29%
16.60%
15.44%
12.94%
9.13%
15.64%
12.91%
5.69%
11.40%
16.05%
26.00%
PAT Growth
11.88%
15.39%
33.02%
60.22%
-37.92%
22.17%
134.88%
-35.66%
-27.36%
-46.14%
 
EPS
63.18
56.48
48.95
36.80
22.97
36.99
30.28
12.89
20.04
27.59
51.22

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
7,590.69
6,856.15
6,198.07
5,952.95
5,837.17
4,823.22
4,724.35
4,622.19
4,350.13
3,494.10
Share Capital
169.23
169.23
169.23
84.62
84.62
84.62
84.62
84.62
84.62
84.62
Total Reserves
7,421.46
6,686.92
6,028.84
5,868.33
5,752.55
4,738.60
4,639.73
4,537.57
4,265.51
3,409.48
Non-Current Liabilities
2,087.71
2,224.05
2,822.81
2,238.15
2,924.20
3,299.15
3,861.40
4,142.42
2,303.33
1,994.65
Secured Loans
1,191.75
1,603.78
2,496.22
2,123.22
2,941.07
3,302.29
3,909.81
4,105.31
2,229.57
1,839.46
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
1.56
3.11
6.15
11.26
10.62
Long Term Provisions
501.27
444.69
393.06
368.74
369.62
338.34
288.52
286.66
263.04
246.36
Current Liabilities
4,717.19
5,425.25
5,447.30
4,415.09
4,891.62
5,454.16
5,165.32
5,202.17
2,738.26
3,285.48
Trade Payables
1,820.02
2,089.32
1,678.80
1,674.44
2,066.81
2,048.81
2,096.74
2,048.24
1,749.32
2,260.22
Other Current Liabilities
1,143.50
1,130.15
1,578.41
1,365.10
1,635.36
1,860.80
1,641.26
1,151.68
687.14
822.28
Short Term Borrowings
1,249.97
1,637.71
1,765.07
923.04
704.40
1,090.85
934.11
1,625.60
0.00
3.32
Short Term Provisions
503.70
568.07
425.02
452.51
485.05
453.70
493.21
376.65
301.80
199.66
Total Liabilities
14,395.59
14,505.45
14,468.18
12,606.19
13,652.99
13,576.53
13,751.07
13,967.30
9,392.21
8,774.69
Net Block
7,946.90
8,138.11
8,121.45
6,422.65
7,064.63
7,533.12
7,747.71
7,854.68
3,688.44
2,859.08
Gross Block
14,041.34
13,484.57
12,811.62
10,728.19
10,511.53
10,334.13
9,935.43
9,449.48
4,909.80
3,793.53
Accumulated Depreciation
6,094.44
5,346.46
4,690.17
4,305.54
3,446.90
2,801.01
2,187.72
1,594.80
1,221.36
934.45
Non Current Assets
8,773.02
8,893.97
9,139.00
7,311.54
8,129.77
8,595.61
8,713.53
8,704.89
4,512.74
4,085.66
Capital Work in Progress
478.14
360.51
765.40
629.82
889.38
711.93
617.12
646.94
519.49
1,041.58
Non Current Investment
43.57
31.80
42.70
42.33
42.09
2.09
2.09
0.09
0.09
0.09
Long Term Loans & Adv.
294.29
349.34
181.04
166.55
96.84
222.19
150.58
130.96
182.32
99.66
Other Non Current Assets
10.12
14.21
28.41
50.19
36.83
126.28
196.03
72.22
122.40
85.25
Current Assets
5,622.57
5,611.48
5,313.72
5,164.99
5,521.50
4,979.06
5,037.53
5,262.32
4,879.38
4,688.21
Current Investments
112.21
141.04
156.09
183.98
139.05
0.02
351.35
492.27
803.55
779.59
Inventories
2,541.25
2,279.07
2,229.64
2,462.32
2,681.20
2,148.22
1,935.15
1,966.30
1,559.15
1,357.98
Sundry Debtors
1,866.45
1,844.30
1,943.82
1,632.48
1,523.37
1,649.34
1,435.71
1,253.45
950.89
1,445.09
Cash & Bank
579.46
839.04
571.46
403.41
603.50
666.65
816.04
867.23
893.72
647.03
Other Current Assets
523.20
327.99
246.89
331.62
574.38
514.83
499.28
683.07
672.07
458.52
Short Term Loans & Adv.
199.58
180.04
165.82
151.18
63.41
73.48
93.46
95.39
82.62
90.18
Net Current Assets
905.38
186.23
-133.58
749.90
629.88
-475.10
-127.79
60.15
2,141.12
1,402.73
Total Assets
14,395.59
14,505.45
14,452.72
12,476.53
13,651.27
13,574.67
13,751.06
13,967.21
9,392.12
8,773.87

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
2,585.11
3,266.08
2,368.13
1,802.99
2,005.35
1,392.91
1,798.08
894.15
1,008.84
2,742.12
PBT
2,672.81
2,352.11
1,847.16
1,225.91
1,526.26
1,186.57
561.66
931.01
1,088.09
2,343.44
Adjustment
996.05
993.99
937.24
1,349.95
992.84
876.21
1,418.19
606.92
430.27
552.44
Changes in Working Capital
-480.93
418.08
-18.20
-351.85
-338.25
-385.83
99.39
-360.16
-125.21
423.58
Cash after chg. in Working capital
3,187.93
3,764.18
2,766.20
2,224.01
2,180.85
1,676.95
2,079.24
1,177.77
1,393.15
3,319.46
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-602.82
-498.10
-398.07
-421.02
-175.50
-284.04
-281.16
-283.62
-384.31
-577.34
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-540.05
-167.90
-2,415.31
-196.63
-449.42
198.61
-241.28
-4,706.95
-786.91
-837.85
Net Fixed Assets
-476.77
-161.25
-2,494.94
-29.00
-198.83
-378.80
-610.74
-4,245.22
-592.01
-471.42
Net Investments
-59.42
-102.10
6.43
-53.72
-179.03
351.33
138.83
310.79
-17.69
-484.32
Others
-3.86
95.45
73.20
-113.91
-71.56
226.08
230.63
-772.52
-177.21
117.89
Cash from Financing Activity
-2,297.99
-2,779.64
77.36
-1,781.05
-1,650.79
-1,549.04
-1,314.45
3,417.39
-192.91
-1,435.15
Net Cash Inflow / Outflow
-252.93
318.54
30.18
-174.69
-94.86
42.48
242.35
-395.41
29.02
469.12
Opening Cash & Equivalents
835.14
508.53
398.40
572.56
661.82
588.76
702.04
1,067.57
1,049.86
612.38
Closing Cash & Equivalent
573.48
835.14
508.53
398.40
572.56
661.82
940.06
702.04
1,067.57
1,049.86

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
224.27
202.57
183.13
175.87
172.45
284.99
279.15
273.11
257.04
206.46
ROA
13.23%
11.43%
9.20%
5.92%
9.20%
7.50%
3.15%
5.81%
10.28%
20.89%
ROE
26.46%
25.38%
20.50%
13.18%
23.49%
21.47%
9.34%
15.12%
23.80%
57.92%
ROCE
27.32%
24.28%
20.32%
14.35%
17.62%
15.28%
9.75%
13.81%
20.36%
45.63%
Fixed Asset Turnover
1.22
1.27
1.39
1.43
1.43
1.48
1.50
1.57
1.35
1.82
Receivable days
40.18
41.38
39.99
37.86
38.92
37.65
33.78
35.74
74.66
82.76
Inventory Days
52.20
49.26
52.47
61.71
59.24
49.84
49.01
57.16
90.90
66.19
Payable days
279.17
279.66
243.50
306.08
383.19
133.47
139.05
150.99
171.27
204.35
Cash Conversion Cycle
-186.79
-189.03
-151.04
-206.50
-285.04
-45.98
-56.26
-58.09
-5.72
-55.41
Total Debt/Equity
0.40
0.57
0.85
0.68
0.83
1.21
1.28
1.40
0.58
0.67
Interest Cover
11.59
7.65
6.54
5.81
5.32
3.63
2.11
4.02
6.29
13.74

News Update:


  • Torrent Pharma’s consolidated net profit falls 22% in Q4
    25th May 2026, 12:21 PM

    The total consolidated income of the company has increased by 42.13% at Rs 4,180.00 crore for Q4FY26

    Read More
  • Torrent Pharma - Quarterly Results
    23rd May 2026, 00:00 AM

    Read More
  • USFDA concludes inspection at Torrent Pharmaceuticals’ Bileshwarpura facility
    13th Apr 2026, 10:29 AM

    The inspection has been concluded with zero observation

    Read More
  • Torrent Pharmaceuticals launches Semaglutide brands in India
    21st Mar 2026, 18:00 PM

    The launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.